| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 70860-0202-10 | 70860-0202 | Pemetrexed disodium | Pemetrexed | 100.0 mg/4.2mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 25, 2022 | Feb 29, 2024 | No Longer Used |
| 51407-0872-12 | 51407-0872 | Pazopanib | Pazopanib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, PDGFR, FGFR, Kit, Itk, Lek, c-Fms | Oral | Jan 8, 2024 | In Use | |
| 50242-0090-01 | 50242-0090 | Vemurafenib | Zelboraf | 240.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF | Oral | Aug 17, 2011 | Feb 28, 2018 | In Use |
| 63323-0763-50 | 63323-0763 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Mar 20, 2009 | In Use | |
| 70860-0200-05 | 70860-0200 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Mar 24, 2017 | Dec 31, 2024 | No Longer Used |
| 45963-0613-53 | 45963-0613 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jul 19, 2018 | Jul 31, 2022 | No Longer Used |
| 61703-0349-09 | 61703-0349 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Feb 27, 2008 | In Use | |
| 44087-5000-06 | 44087-5000 | Tepotinib Hydrochloride | TEPMETKO | 225.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | MET | Oral | Feb 3, 2021 | In Use | |
| 62559-0930-01 | 62559-0930 | CYCLOPHOSPHAMIDE | CYCLOPHOSPHAMIDE | 25.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | Jun 22, 2020 | Mar 31, 2023 | No Longer Used |
| 00703-5653-01 | 00703-5653 | Etoposide | Toposar | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Aug 1, 1996 | In Use | |
| 54868-0173-00 | 54868-0173 | methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intrathecal, Intravenous | Mar 26, 2003 | In Use | |
| 72603-0420-01 | 72603-0420 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan 11, 2024 | Mar 31, 2027 | In Use |
| 68001-0390-77 | 68001-0390 | Mitomycin | Mitomycin | 20.0 mg/40mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | May 14, 2019 | In Use | |
| 71335-2221-05 | 71335-2221 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Aug 15, 2023 | In Use | |
| 43598-0055-04 | 43598-0055 | Nilotinib | Nilotinib | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 19, 2025 | In Use | |
| 16729-0231-64 | 16729-0231 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jul 30, 2012 | Jun 21, 2019 | In Use |
| 47335-0929-87 | 47335-0929 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb 13, 2014 | In Use | |
| 43598-0603-30 | 43598-0603 | Dasatinib | Dasatinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use | |
| 00069-4032-01 | 00069-4032 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Mar 5, 2013 | Aug 31, 2021 | No Longer Used |
| 59572-0710-30 | 59572-0710 | Enasidenib mesylate | Idhifa | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | IDH2 | Oral | Aug 1, 2017 | In Use | |
| 57277-0002-10 | 57277-0002 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Sep 21, 2017 | In Use | |
| 50268-0762-11 | 50268-0762 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Mar 23, 2017 | In Use | |
| 72603-0256-01 | 72603-0256 | Everolimus | EVEROLIMUS | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Oct 1, 2024 | In Use | |
| 75834-0190-01 | 75834-0190 | Decitabine | Decitabine | 50.0 mg/20mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec 17, 2020 | In Use | |
| 83076-1100-06 | 83076-1100 | Ensartinib | ENSACOVE | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK, ROS1, MET | Oral | Apr 30, 2025 | In Use |
Found 12250 results — Export these results
Home